首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Revascularization Outcomes in Patients With Acute Limb Ischemia and Active Neoplastic Disease
【24h】

Revascularization Outcomes in Patients With Acute Limb Ischemia and Active Neoplastic Disease

机译:急性肢体缺血和活性肿瘤疾病患者的血运重建结果

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose To report the outcomes of surgical (ST), endovascular (ET), and hybrid (HT) treatment in cancer patients with acute limb ischemia (ALI). Materials and Methods A multicenter retrospective registry collected 139 patients (mean age 72.3 +/- 12.4 years; 73 men) with ALI and active malignancy treated by ET (41, 29%), ST (70, 51%), or HT (28, 20%) in 7 European centers between July 2007 and February 2019. In 22 cases (16%) ALI was the first manifestation of the malignancy. Lung cancer was the most common diagnosis (38, 27%). The primary composite outcome was amputation-free survival (AFS). Overall survival, amputation-free time (AFT), and reintervention-free time (RFT) were also assessed. Cox regression analysis was applied to identify independent risk factors for the primary and secondary outcomes. Results are presented as the hazard ratio (HR) and 95% confidence intervals (CIs). Results ET was associated with improved 12-month AFS compared with both ST (HR 2.27, 95% CI 1.20 to 4.28, p=0.002) and HT (HR 2.14, 95% CI 1.09 to 4.18, p=0.008). ST (HR 2.50, 95% CI 1.19 to 5.53, p=0.003) and HT (HR 3.10, 95% CI 1.45 to 6.65, p<0.001) were related to an increased risk for mortality compared with ET. At 12 months, the AFT was similar between the 3 groups (ET vs ST: HR 1.52, 95% CI 0.51 to 4.53, p=0.45 and ET vs HT: HR 1.21, 95% CI 0.36 to 4.11, p=0.73). The 12-month RFT also did not differ significantly between the 3 treatment options (ET vs ST: HR 1.10, 95% CI 0.49 to 2.46, p=0.79 and ET vs HT: HR 0.51, 95% CI 0.22 to 1.17, p=0.19). ST and/or HT increased the risk for the major amputation and/or death (HR 1.76, 95% CI 1.05 to 2.05, p=0.03), while Rutherford class I ischemia (HR 0.12, 95% CI 0.02 to 0.90, p=0.04) and previous vascular interventions on the index limb (HR 0.55, 95% CI 0.32 to 0.97, p=0.04) showed a protective effect. Conclusion In patients with ALI and active malignant disease, ET was associated with increased AFS and overall survival compared with both ST and HT, while the limb salvage and reintervention rates were comparable among the 3 groups.
机译:目的报告癌症患者急性肢体缺血(ALI)的外科(ST)、血管内(ET)和混合(HT)治疗的结果。材料和方法多中心回顾性登记收集了2007年7月至2019年2月期间在7个欧洲中心接受ET(41,29%)、ST(70,51%)或HT(28,20%)治疗的139例ALI和活动性恶性肿瘤患者(平均年龄72.3+/-12.4岁;73名男性)。在22例(16%)中,ALI是恶性肿瘤的第一表现。肺癌是最常见的诊断(38,27%)。主要的综合结果是无截肢生存率(AFS)。还评估了总生存率、无截肢时间(AFT)和无再干预时间(RFT)。Cox回归分析用于确定主要和次要结果的独立风险因素。结果以危险比(HR)和95%置信区间(CI)表示。结果与ST(HR 2.27,95%可信区间1.20至4.28,p=0.002)和HT(HR 2.14,95%可信区间1.09至4.18,p=0.008)相比,ET与12个月AFS的改善相关。ST(HR 2.50,95%可信区间1.19至5.53,p=0.003)和HT(HR 3.10,95%可信区间1.45至6.65,p<0.001)与ET相比与死亡率增加相关。12个月时,三组之间的AFT相似(ET与ST:HR 1.52,95%可信区间0.51至4.53,p=0.45,ET与HT:HR 1.21,95%可信区间0.36至4.11,p=0.73)。三种治疗方案之间12个月的RFT也没有显著差异(ET与ST:HR 1.10,95%可信区间0.49至2.46,p=0.79,ET与HT:HR 0.51,95%可信区间0.22至1.17,p=0.19)。ST和/或HT增加了主要截肢和/或死亡的风险(HR 1.76,95%可信区间1.05至2.05,p=0.03),而卢瑟福I级缺血(HR 0.12,95%可信区间0.02至0.90,p=0.04)和之前对指肢的血管干预(HR 0.55,95%可信区间0.32至0.97,p=0.04)显示出保护作用。结论与ST和HT相比,在ALI和活动性恶性疾病患者中,ET与AFS和总生存率增加相关,而三组患者的保肢和再干预率相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号